Wilson Sonsini - ECP

insight detail

Wilson Sonsini Advises Faeth Therapeutics on $47 Million Series A

  • 07/21/22
  • Client Highlights
  • Biotech
  • Life Sciences

On June 30, 2022, Faeth Therapeutics, a cancer metabolism company, announced the completion of a Series A financing of $47 million led by S2G Ventures. Khosla Ventures and Future Ventures also participated in the Series A, along with additional support from Digitalis, KdT Ventures, AgFunder, and Cantos. The company has raised a total of $67 million to date. Wilson Sonsini Goodrich & Rosati represented Faeth Therapeutics in the transaction.

The proceeds of the financing will be used to advance Faeth's clinical trials that combine nutrient control, therapeutics, and digital tools to inhibit cancer metabolism.

The Wilson Sonsini team that represented Faeth Therapeutics in this transaction includes: Jennifer Fang and Andrew Thompson with special assistance from Vern Norviel, Tony Jeffries, Lora Green, Charlotte Kim, Mark Solakian, and Tait Graves.

For more information, please see Faeth Therapeutics’ news release. Further coverage can be found on Business Insider and San Francisco Business Times.

ECP Attorneys:

Copyright © 2023 Wilson Sonsini Goodrich & Rosati. All Rights Reserved.

We use cookies on our site to analyze traffic, enhance your experience, and provide you with tailored content. For more information or to opt-out, visit our privacy policy.